Disc Medicine, Inc./$IRON

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Disc Medicine, Inc.

Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.

Ticker

$IRON
Sector
Primary listing

Employees

125

IRON Metrics

BasicAdvanced
$2.4B
-
-$4.53
2.50
-

Bulls say / Bears say

Disc Medicine secured positive feedback from the FDA in a July 21 2025 pre-NDA meeting, confirming alignment on key CMC and endpoint parameters and keeping the planned October 2025 NDA submission for bitopertin on track (FT.com).
The company completed a $259 million public offering in January 2025, bolstering its balance sheet and extending its cash runway into at least 2028 (GlobeNewswire).
Disc Medicine is advancing its pipeline beyond EPP, with the Phase 2 DISC-3405 trial in polycythemia vera set to initiate in H1 2025, reflecting diversification of clinical assets (GlobeNewswire).
Net loss widened to $34.1 million in Q1 2025 from $26.9 million in Q1 2024, indicating increased cash burn as the company invests in its pipeline (GlobeNewswire).
Research and development expenses climbed to $27.8 million in Q1 2025 from $23.7 million year-over-year, highlighting rising costs that could pressure future cash flows if trials extend beyond projections (GlobeNewswire).
Selling, general and administrative expenses jumped to $12.2 million in Q1 2025 from $7.8 million, suggesting growing overhead ahead of potential product commercialization without near-term revenue to offset these costs (GlobeNewswire).
Data summarised monthly by Lightyear AI. Last updated on 1 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $IRON

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs